KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Other Non-Current Liabilities

Last Annual Value

32.08M

3-Year CAGR

8%

5-Year CAGR

%

10-Year CAGR

%

KT

Kalaris Therapeutics Inc Competitors Analysis of Other Non-Current Liabilities

KLRS · NASDAQ
CompanyOther Non-Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
32.08M
-10.3%N/AN/A 
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
1.95M
-27.3%-52.1%N/A
192.00K
N/A-29.6%-12.6%
8.51M
91.2%35.9%N/A
37.07M
24.7%131.7%N/A
0.00
N/AN/AN/A
314.00K
45.5%16.7%-2.1%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7